LSL Pharma Group Completes the Acquisition of Virage Santé
2024年6月18日 - 8:00PM
LSL PHARMA GROUP INC. (TSXV: LSL) ("the Company"
or "LSL Pharma"), a Canadian integrated pharmaceutical company, is
pleased to announce the completion of the acquisition of Virage
Santé ("Virage"), a company specializing in the manufacturing and
marketing of natural health products ("NHPs"), based in Lévis,
Quebec. This acquisition increases LSL Pharma's contract
development and manufacturing activities, while creating synergies
with its subsidiary LSL Laboratory Inc. ("LSL").
The purchase price of $2.5 million was paid in
cash for the acquisition of Virage. The transaction includes an
8,000 sq ft manufacturing plant. The acquisition of Virage will
boost LSL Pharma`s revenues by 15-20% annually, as well as broaden
its client base which will benefit from the LSL Group`s expanded
service offering.
In operation since 1994, Virage enjoys a great
reputation for quality and services. It manufactures a range of
NHPs in liquid, powder and capsule form, sold under its own brand
or under private labels. Virage`s manufacturing activities include
blistering, encapsulation, sachet and jar filling, will help expand
LSL’s service portfolio.
"We are very pleased with this acquisition,
which is in line with LSL Pharma's growth strategy of diversifying
our service offering and increasing our contract manufacturing
operations to better serve the pharmaceutical sector," says
François Roberge, President and CEO. " The company will continue to
operate from its current plant and will be supported by LSL
Pharma's head office," concludes Mr. Roberge.
CAUTION
REGARDING FORWARD-LOOKING
STATEMENTS
This press release may contain forward-looking
statements as defined under applicable Canadian securities
legislation. Forward-looking statements can generally be identified
by the use of forward-looking terminology such as "may", "will",
"expect", "intend", "estimate", "continue" or similar expressions.
Forward-looking statements are based on a number of assumptions and
are subject to various known and unknown risks and uncertainties,
many of which are beyond the Corporation's ability to control or
predict, that could cause actual results or performance to differ
materially from those expressed or implied in such forward-looking
statements. These risks and uncertainties include, but are not
limited to, those identified in the Corporation's filings with
Canadian securities regulatory authorities, such as legislative or
regulatory developments, increased competition, technological
change and general economic conditions. All forward-looking
statements made herein should be read in conjunction with such
documents.
Readers are cautioned not to place undue
reliance on forward-looking statements. No assurance can be given
that any of the events referred to in the forward-looking
statements will transpire, and if any of them do, the actual
results, performance or achievements of the Corporation may differ
materially from those expressed or implied by the forward-looking
statements. All forward-looking statements contained in this press
release speak only as of the date of this press release. The
Corporation does not undertake to update these forward-looking
statements, whether as a result of new information, future events
or otherwise, except as required by law.
ABOUT LSL
PHARMA GROUP
INC.
LSL Pharma Group Inc. is an integrated Canadian
pharmaceutical company specializing in the development,
manufacturing, and commercialization of high-quality sterile
ophthalmic pharmaceuticals, as well as natural health products in
solid dosage forms. For further information, please visit the
following website www.groupelslpharma.com.
ABOUT VIRAGE
SANTÉ INC.
For more information on the company, please
visit www.viragesante.com.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
CONTACT
François Roberge
President and Chief Executive Officer
(514) 664-7700
E-mail: Investors@groupelslpharma.com
OR
Luc Mainville
Executive VP & Chief Financial Officer
(514) 664-7700 ext.: 301
E-mail : lmainville@groupelslpharma.com
LSL Pharma (TSXV:LSL)
過去 株価チャート
から 10 2024 まで 11 2024
LSL Pharma (TSXV:LSL)
過去 株価チャート
から 11 2023 まで 11 2024